Use and abuse of taxanes in the management of metastatic breast cancer

被引：15

作者：

Bernard-Marty, C ^{[1
]}

Cardoso, F ^{[1
]}

Piccart, MJ ^{[1
]}

机构：

[1] Inst Jules Bordet, Dept Med Oncol, B-1000 Brussels, Belgium

来源：

EUROPEAN JOURNAL OF CANCER | 2003年 / 39卷 / 14期

关键词：

D O I：

10.1016/S0959-8049(03)00538-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Taxanes are currently introduced early in the treatment of patients with metastatic breast cancer (MBC), both as single agents and in combination with anthracyclines. Two different patient populations exist: those with no or minimal prior anthracycline exposure and those who have failed previous anthracyclines. The data generated through phase III trials in first-line MBC therapy will be reviewed and their interpretation for routine clinical practice (use versus abuse) will be discussed. Ways of improving taxane-based treatment tailoring both in the pre- and postgenomic eras will be addressed. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：1978 / 1989

页数：12

共 40 条

[1]

[Anonymous], 2002, P AM SOC CLIN ONCOL

[2]

[Anonymous], P AM SOC CLIN ONCOL

[3]

BELLOT R, 1998, P AN M AM SOC CLIN, V17, pA221

[4]

Bernard-Marty Chantal, 2002, Clin Breast Cancer, V3, P341, DOI 10.3816/CBC.2002.n.037

[5] Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial [J].

Biganzoli, L ;

Cufer, T ;

Bruning, P ;

Coleman, R ;

Duchateau, L ;

Calvert, AH ;

Gamucci, T ;

Twelves, C ;

Fargeot, P ;

Epelbaum, R ;

Lohrisch, C ;

Piccart, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (14) :3114-3121

[6] Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer [J].

Bishop, JF ;

Dewar, J ;

Toner, GC ;

Smith, J ;

Tattersall, MHN ;

Olver, IN ;

Ackland, S ;

Kennedy, I ;

Goldstein, D ;

Gurney, H ;

Walpole, E ;

Levi, J ;

Stephenson, J ;

Canetta, R .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2355-2364

[7] Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure [J].

Bonneterre, J ;

Roché, H ;

Monnier, A ;

Guastalla, JP ;

Namer, M ;

Fargeot, P ;

Assadourian, S .

BRITISH JOURNAL OF CANCER, 2002, 87 (11) :1210-1215

[8]

CARMICHAEL J, 2001, P AN M AM SOC CLIN, V20, pA22

[9] Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer [J].

Chan, S ;

Friedrichs, K ;

Noel, D ;

Pintér, T ;

Van Belle, S ;

Vorobiof, D ;

Duarte, R ;

Gil, MG ;

Bodrogi, I ;

Murray, E ;

Yelle, L ;

von Minckwitz, G ;

Korec, S ;

Simmonds, P ;

Buzzi, F ;

Mancha, RG ;

Richardson, G ;

Walpole, E ;

Ronzoni, M ;

Murawsky, M ;

Alakl, M ;

Riva, A ;

Crown, J .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2341-2354

[10]

DILEO A, 2002, P AM SOC CLIN ONCOL, V21

← 1 2 3 4 →